Compass Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary

Compass Therapeutics

12/05/2025 14:31

Compass Therapeutics Inc. CMPX.OQ reported a quarterly adjusted loss of 12 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -8 cents.  The mean expectation of ten analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -15 cents to -5 cents per share.

Reported revenue was zero​; analysts expected zero.

Compass Therapeutics Inc.'s reported EPS for the quarter was a loss of 12 cents​.

The company reported a quarterly loss of $16.63 million.

Compass Therapeutics Inc. shares had fallen by 4.2% this quarter and gained 25.5% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 23.3% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Compass Therapeutics Inc. is $10.00

This summary was machine generated from LSEG data May 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.11
-0.12
Missed
Dec. 31 2024
-0.10
-0.11
Missed
Sep. 30 2024
-0.11
-0.08
Beat
Jun. 30 2024
-0.09
-0.10
Missed